Genomic Assays for Chemotherapy Decisions in ER-Positive/HER2-Negative Breast Cancer

During a Targeted Oncology™ Case-Based Roundtable™ event, Mark Pegram, MD, and participants discussed their next steps for a patient with breast cancer after progression on aromatase inhibitor plus palbociclib, including repeat biomarker testing.

In season 3, episode 3 of Targeted Talks, William J. Gradishar, MD, discusses the latest version of the NCCN Clinical Practice Guideline for managing early-stage breast cancer.

In an interview with Targeted Oncology, Joshua K. Sabari, MD, discussed drug shortages and how they are affecting clinicians and patients in the oncology space.

In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.

A sustained overall survival benefit has been reported from the phase 3 TROPiCS-02 study.

Patritumab deruxtecan treatment yielded efficacy results and was safe for patients with metastatic breast cancer.